Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate for Alcohol Use Disorder
NCT06269627Phase 4Recruiting
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of acamprosate in alcohol use disorder (AUD) (2 arms), sponsored by National Institute on Alcohol Abuse and Alcoholism. Primary endpoint: Reduction of beta power at 21 days. Started May 2025; status: recruiting.
02
Drugs
acamprosate
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06269627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06269627.